Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer

Recruiting now · Not applicable

Conditions studied: Advanced Breast Cancer

In brief

To compare the efficacy and safety of capecitabine and cyclophosphamide (XC) versus physician's choice as maintenance therapy for patients with advanced breast cancer who achieved disease control after salvage treatment.

Key facts

Study ID

NCT05876065

Run by

Wenjin Yin

People needed

86

Starts

2023-06-01

Expected to finish

2027-02-01

Last updated by the study team

2025-09-11

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female, age≥18 years old
• ECOG≤2
• Pathologically confirmed primary breast cancer, with pathologically or radiologically confirmed recurrent or metastatic lesions
• HR+/HER2+ or HR-/HER2+ or HR-/HER2-
• At least one measurable lesion or bone-only disease (osteolytic or mixed) according to RECIST v1.1
• Disease control (complete response + partial response + stable disease) after salvage treatment
• Expected survival ≥6 months
• Adequate organ function

You may not qualify if…

• during pregnancy and lactation
• Patients with central nervous system metastasis

Where it is running

• Renji Hospital, School of Medicine, Shanghai Jiaotong University — Shanghai, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.